The estimated Net Worth of Saundra L Pelletier is at least $3.47 Million dollars as of 27 May 2022. Ms. Pelletier owns over 141,000 units of Evofem Biosciences Inc stock worth over $2,130 and over the last 7 years she sold EVFM stock worth over $665,785. In addition, she makes $2,803,980 as President, Chief Executive Officer, and Director at Evofem Biosciences Inc.
Saundra has made over 12 trades of the Evofem Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 141,000 units of EVFM stock worth $49,350 on 27 May 2022.
The largest trade she's ever made was buying 141,000 units of Evofem Biosciences Inc stock on 27 May 2022 worth over $49,350. On average, Saundra trades about 15,880 units every 40 days since 2018. As of 27 May 2022 she still owns at least 236,722 units of Evofem Biosciences Inc stock.
You can see the complete history of Ms. Pelletier stock trades at the bottom of the page.
Saundra Pelletier serves as President, Chief Executive Officer, Director of the Company. Ms. Pelletier brings more than two decades of broad executive leadership experience to Evofem, including a strong track record driving multiple billion-dollar product launches, expanding commercial capabilities in ex-U.S. markets and advocating for women’s health. Throughout her career, she has had oversight and accountability for Sales, Marketing, Operations, Medical Affairs, Regulatory Affairs, Manufacturing, Customer Service, Business Development, and Strategic Partnerships. Ms. Pelletier was previously the founding CEO of WomanCare Global (WCG), an international nonprofit focused on creating sustainable supply chains that delivered products to women in more than 100 developing countries. Under her leadership, WCG secured approximately $68M in committed funding from major foundations and organizations, and launched an innovative United States educational campaign with American actress/activist Jessica Biel. She served as a member of the Board of Directors from November 2017 to February 2020. Earlier in her career, Ms. Pelletier served as Corporate Vice President and Global Franchise Leader for G.D. Searle, where she managed a $250 million business unit focused on women’s healthcare. She later moved to Women First Healthcare, where she served as Vice President of Pharmaceuticals and raised $40 million in capital. Ms. Pelletier is a published author, skilled moderator and coveted keynote speaker.
As the President, Chief Executive Officer, and Director of Evofem Biosciences Inc, the total compensation of Saundra Pelletier at Evofem Biosciences Inc is $2,803,980. There are no executives at Evofem Biosciences Inc getting paid more.
Saundra Pelletier is 46, she's been the President, Chief Executive Officer, and Director of Evofem Biosciences Inc since 2018. There are 14 older and no younger executives at Evofem Biosciences Inc. The oldest executive at Evofem Biosciences Inc is Gillian Greer, 75, who is the Independent Director.
Saundra's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 7770 REGENTS RD, SUITE 113-618, SAN DIEGO, CA, 92122.
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link, and Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
Evofem Biosciences Inc executives and other stock owners filed with the SEC include: